133 STAT. 959  PUBLIC LAW 116–22—JUNE 24, 2019  (i) capabilities of the United States to leverage  genomic engineering technologies as a part of the med- ical countermeasure enterprise, including current  applicable research, development, and application  efforts underway within the Department of Defense;  (ii) the potential for state and non-state actors  to utilize genomic engineering technologies as a  national health security threat; and  (iii) security measures to monitor and assess the  potential threat that may result from utilization of  genomic engineering technologies and related tech- nologies for the purpose of compromising national  health security.  Recommenda-  tions.  (b) REPORT.—Not later than 270 days after the meeting  described in subsection (a) is held, the Assistant Secretary for  Preparedness and Response shall issue a report to the congressional  committees of jurisdiction on the topics discussed at such meeting,  and provide recommendations, as applicable, to utilize innovations  in genomic engineering (including genome editing) and related tech- nologies as a part of preparedness and response activities to advance  national health security. Such report shall be issued in a manner  that does not compromise national security.  Not later than one year after the date of the enactment of  this Act, the Secretary of Health and Human Services shall submit  to the Committee on Health, Education, Labor, and Pensions of  the Senate and the Committee on Energy and Commerce of the  House of Representatives a report describing efforts and activities  to coordinate with other countries and international partners during  recent public health emergencies with respect to the research and  advanced research on, and development of, qualified pandemic or  epidemic products (as defined in section 319F–3 of the Public Health  Service Act (42 U.S.C. 247d–6d)). Such report may include informa- tion regarding relevant work carried out under section 319L(c)(5)(E)  of the Public Health Service Act (42 U.S.C. 247d–7e(c)(5)(E)),  through public-private partnerships, and through collaborations  with other countries to assist with or expedite the research and  development of qualified pandemic or epidemic products. Such  report shall not include information that may compromise national  security.  SEC. 606. REPORT ON VACCINES DEVELOPMENT.  SEC. 607. STRENGTHENING MOSQUITO ABATEMENT FOR SAFETY AND  HEALTH.  (a) REAUTHORIZATION OF MOSQUITO ABATEMENT FOR SAFETY  AND HEALTH PROGRAM.—Section 317S (42 U.S.C. 247b–21) is  amended—  (1) in subsection (a)(1)(B)—  (A) by inserting ‘‘including programs to address  emerging infectious mosquito-borne diseases,’’ after ‘‘sub- divisions for control programs,’’; and  (B) by inserting ‘‘or improving existing control pro- grams’’ before the period at the end;  (2) in subsection (b)—  (A) in paragraph (1), by inserting ‘‘, including improve- ment,’’ after ‘‘operation’’;  (B) in paragraph (2)—  (i) in subparagraph (A)— 